Lack of beta(2)-AR improves exercise capacity and skeletal muscle oxidative phenotype in mice

Imagem de Miniatura
Arquivos
art_SALEMI_Lack_of_beta(2)_AR_improves_exercise_capacity_and_2012.PDF (1.12 MB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2012
Editora
WILEY-BLACKWELL
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
VOLTARELLI, V. A.
BACURAU, A. V. N.
BECHARA, L. R. G.
BUENO JUNIOR, C. R.
BOZI, L. H. M.
MATTOS, K. C.
BRUM, P. C.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS, v.22, n.6, p.e125-e132, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
beta(2)-adrenergic receptor (beta(2)-AR) agonists have been used as ergogenics by athletes involved in training for strength and power in order to increase the muscle mass. Even though anabolic effects of beta(2)-AR activation are highly recognized, less is known about the impact of beta(2)-AR in endurance capacity. We presently used mice lacking beta(2)-AR [beta(2)-knockout (beta(2) KO)] to investigate the role of beta(2)-AR on exercise capacity and skeletal muscle metabolism and phenotype. beta(2) KO mice and their wild-type controls (WT) were studied. Exercise tolerance, skeletal muscle fiber typing, capillary-to-fiber ratio, citrate synthase activity and glycogen content were evaluated. When compared with WT, beta 2KO mice displayed increased exercise capacity (61%) associated with higher percentage of oxidative fibers (21% and 129% of increase in soleus and plantaris muscles, respectively) and capillarity (31% and 20% of increase in soleus and plantaris muscles, respectively). In addition, beta 2KO mice presented increased skeletal muscle citrate synthase activity (10%) and succinate dehydrogenase staining. Likewise, glycogen content (53%) and periodic acid-Schiff staining (glycogen staining) were also increased in beta 2KO skeletal muscle. Altogether, these data provide evidence that disruption of beta(2)AR improves oxidative metabolism in skeletal muscle of beta 2KO mice and this is associated with increased exercise capacity.
Palavras-chave
skeletal muscle, endurance capacity, metabolism, beta(2)-adrenergic receptors, genetic animal model
URI
https://observatorio.fm.usp.br/handle/OPI/1536
Referências
  1. AIGNER A, 1990, WIEN MED WOCHENSCHR, V140, P163
  2. BALMAIN JUDITH H., 1956, AUSTRALIAN JOUR BIOL SCI, V9, P139
  3. Beloka S, 2008, MED SCI SPORT EXER, V40, P1932, DOI 10.1249/MSS.0b013e31817fbe11
  4. Bricout VA, 2004, ACTA PHYSIOL SCAND, V180, P271, DOI 10.1046/j.0001-6772.2003.01246.x
  5. BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369
  6. Brum PC, 2002, AM J PHYSIOL-HEART C, V283, pH1838, DOI 10.1152/ajpheart.01063.2001
  7. Burniston JG, 2007, MUSCLE NERVE, V35, P217, DOI 10.1002/mus.20684
  8. Busquets S, 2004, CANCER RES, V64, P6725, DOI 10.1158/0008-5472.CAN-04-0425
  9. Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694
  10. Crabtree B, 1979, MEASUREMENT ENZYME A, P1
  11. CURI R, 1986, BIOCHEM BIOPH RES CO, V138, P318, DOI 10.1016/0006-291X(86)90282-2
  12. ELFELLAH MS, 1989, BRIT J CLIN PHARMACO, V27, P31
  13. Ferreira JCB, 2007, CLIN EXP PHARMACOL P, V34, P760, DOI 10.1111/j.1440-1681.2007.04635.x
  14. Gehrig SM, 2010, AM J PATHOL, V176, P29, DOI 10.2353/ajpath.2010.090760
  15. Harcourt LJ, 2007, NEUROMUSCULAR DISORD, V17, P47, DOI 10.1016/j.nmd.2006.08.012
  16. Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646
  17. Hinkle RT, 2002, MUSCLE NERVE, V25, P729, DOI 10.1002/mus.10092
  18. Jensen J, 2002, PFLUG ARCH EUR J PHY, V444, P213, DOI 10.1007/s00424-002-0793-1
  19. KIM YS, 1991, BIOCHEM PHARMACOL, V42, P1783, DOI 10.1016/0006-2952(91)90516-8
  20. Kline WO, 2007, J APPL PHYSIOL, V102, P740, DOI 10.1152/japplphysiol.00873.2006
  21. Koopman R, 2010, J PHYSIOL-LONDON, V588, P4811, DOI 10.1113/jphysiol.2010.196725
  22. LO S, 1970, J APPL PHYSIOL, V28, P234
  23. Lynch GS, 2008, PHYSIOL REV, V88, P729, DOI 10.1152/physrev.00028.2007
  24. MALTIN CA, 1993, BIOSCIENCE REP, V13, P159, DOI 10.1007/BF01149960
  25. MOORE NG, 1994, AM J PHYSIOL, V267, pE475
  26. NACHLAS MM, 1957, J HISTOCHEM CYTOCHEM, V5, P420
  27. Nystad W, 2000, MED SCI SPORT EXER, V32, P266, DOI 10.1097/00005768-200002000-00003
  28. REEDS PJ, 1986, BRIT J NUTR, V56, P249, DOI 10.1079/BJN19860104
  29. Robinson MM, 2010, AM J PHYSIOL-REG I, V298, pR25, DOI 10.1152/ajpregu.00524.2009
  30. Ryall JG, 2004, J PHYSIOL-LONDON, V555, P175, DOI 10.1113/jpjysiol.2003.056770
  31. Ryall JG, 2006, BRIT J PHARMACOL, V147, P587, DOI 10.1038/sj.bjp.0706669
  32. Ryall JG, 2007, J GERONTOL A-BIOL, V62, P813
  33. SILLAU AH, 1977, PFLUG ARCH EUR J PHY, V369, P269, DOI 10.1007/BF00582194
  34. Turgeman T, 2008, NEUROMUSCULAR DISORD, V18, P857, DOI 10.1016/j.nmd.2008.06.386
  35. van Baak MA, 2000, MED SCI SPORT EXER, V32, P1300, DOI 10.1097/00005768-200007000-00018
  36. VANMIL HGJ, 1995, BRIT J PHARMACOL, V116, P2881
  37. Vieira NM, 2008, STEM CELLS, V26, P2391, DOI 10.1634/stemcells.2008-0043
  38. Wolfarth B, 2010, ENDOCRIN METAB CLIN, V39, P75, DOI 10.1016/j.ecl.2009.10.005
  39. Wolfarth B, 2007, METABOLISM, V56, P1649, DOI 10.1016/j.metabol.2007.07.006
  40. YANG YT, 1989, BIOCHEM J, V261, P1
  41. ZEMAN RJ, 1988, AM J PHYSIOL, V254, pE726

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11